Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Next Previous
Trial Profile

A Phase 1/2 Study of Tegavivint (NSC#826393) in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tegavivint (Primary)
  • Indications Adenocarcinoma; Carcinoma; Colorectal cancer; Endometrial cancer; Ewing's sarcoma; Fibroma; Hepatoblastoma; Liver cancer; Malignant melanoma; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Ovarian cancer; Pancreatic ductal carcinoma; Solid tumours; Wilms' tumour
  • Focus Adverse reactions; Pharmacokinetics

Most Recent Events

  • 13 Apr 2026 According to an Iterion Therapeutics media release, data from the trial will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting.
  • 19 Apr 2023 Results of the pediatric early phase clinical trials network (n=15) assessing the safety and tolerability of tegavivint n children, adolescents, and young adults with recurrent or refractory solid tumors, including lymphomas and desmoid tumors, presented at the 114th Annual Meeting of the American Association for Cancer Research.
  • 31 Aug 2022 Planned number of patients changed from 38 to 147.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top